Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Clinical Trials01:16

Clinical Trials

11.1K
Clinical trials are prospective experimental studies conducted on humans to determine the safety and efficacy of treatments, drugs, diet methods, and medical devices. Using statistics in clinical trials enables researchers to derive reasonable and accurate conclusions from the collected data, allowing them to make wise decisions in uncertain situations. In medical research, statistical methods are crucial for preventing errors and bias.
There are four phases in a clinical trial. A phase one...
11.1K
Clinical Trials: Overview01:11

Clinical Trials: Overview

5.4K
Clinical development focuses on how the drug will interact with the human body and encompasses four key phases of clinical trials, each serving a specific purpose in assessing the safety and effectiveness of new drugs. These phases overlap and build upon one another. Phase I involves a small group of healthy volunteers (typically 20-80 individuals) or, in cases where significant toxicity is expected, patients with the targeted disease, such as cancer or AIDS. The volunteers are tested for...
5.4K
Blinding01:11

Blinding

4.0K
Blinding is a commonly used method of not telling participants which treatment a subject is receiving. Blinding is a critical part of a randomized control trial or RCT. It reduces the bias that affects the results. In an RCT, blinding is used in the form of a placebo. A placebo effect occurs when untreated subjects falsely believe they have received the treatment and report improved symptoms. A placebo or a dummy treatment is administered to subjects to negate the bias caused by such an effect.
4.0K
Preclinical Development: Overview01:28

Preclinical Development: Overview

6.4K
Preclinical development consists of a series of tests that ensure the safety and efficacy of a new therapeutic compound before it is tested in humans. There are four main phases to this process. First, safety pharmacology tests are conducted to ensure the drug does not produce any acutely harmful effects. These tests examine parameters such as bronchoconstriction, cardiac dysrhythmias, blood pressure changes, and ataxia. Next, preliminary toxicological testing is performed to determine the...
6.4K
Crossover Experiments01:16

Crossover Experiments

4.7K
Crossover experiments, also called the repeated-measurements design, is a study design in which all experimental units are exposed to all treatments in different periods. Crossover experiments are generally used in psychology, the pharmaceutical industry, agriculture, and medicine.
Crossover designs are performed even with smaller sample sizes since the samples can act as their controls. These are better than simple randomized trials since patients are exposed to all the treatments.
4.7K
Bioavailability Study Design: Healthy Subjects Versus Patients01:15

Bioavailability Study Design: Healthy Subjects Versus Patients

202
Bioavailability studies are essential for evaluating a drug's therapeutic efficacy and understanding its absorption patterns under various physiological conditions. Conducting such studies on target patient populations provides more relevant data by simulating real-world disease states. However, practical challenges often necessitate the use of young, healthy adult volunteers as study subjects.Patients may exhibit altered drug absorption patterns due to the effects of the disease itself,...
202

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

A cross-sectional study of gender differences in quality of life domains in patients with neurofibromatosis type 1.

Orphanet journal of rare diseases·2022
Same author

Chronic immunoglobulin maintenance therapy in myasthenia gravis.

European journal of neurology·2020
Same author

Comparison of the single simple question and the patient acceptable symptom state in myasthenia gravis.

European journal of neurology·2020
Same author

Chronic stress, depression and personality type in patients with myasthenia gravis.

European journal of neurology·2019
Same author

Patient-reported outcomes with subcutaneous immunoglobulin in chronic inflammatory demyelinating polyneuropathy: the PATH study.

European journal of neurology·2019
Same author

EQ-5D-5L and SF-6D health utility index scores in patients with myasthenia gravis.

European journal of neurology·2018
Same journal

Glutamate-Glutamine metabolism and transport, implications in Parkinson's disease.

International review of neurobiology·2026
Same journal

Redox bioenergetics of neuronal senescence in Alzheimer's disease.

International review of neurobiology·2026
Same journal

Neurovascular coupling and energy substrate delivery in Alzheimer's disease.

International review of neurobiology·2026
Same journal

From metals to mitochondria: Linking trace elements to energy crisis in Alzheimer's disease.

International review of neurobiology·2026
Same journal

Invisible threats of microplastics induced toxicity: Oxidative and inflammatory pathways in the CNS and retina.

International review of neurobiology·2026
Same journal

Starved synapses: Gut microbiome dysbiosis and its role in Alzheimer's glucose impairment.

International review of neurobiology·2026
See all related articles

Related Experiment Video

Updated: Mar 21, 2026

A Clinical Trial Assessing the Safety, Efficacy, and Delivery of Olive-Oil-Based Three-Chamber Bags for Parenteral Nutrition
04:53

A Clinical Trial Assessing the Safety, Efficacy, and Delivery of Olive-Oil-Based Three-Chamber Bags for Parenteral Nutrition

Published on: September 20, 2019

11.4K

The Perfect Clinical Trial.

V Bril1

  • 1Ellen and Martin Prosserman Centre for Neuromuscular Diseases, University Health Network, University of Toronto, Toronto, ON, Canada.

International Review of Neurobiology
|May 3, 2016
PubMed
Summary
This summary is machine-generated.

Clinical trials for diabetic sensorimotor polyneuropathy (DSP) may fail due to design flaws. Optimizing trial design with early-stage patients and longer durations could reveal disease-modifying benefits.

Keywords:
CriteriaDiabetesDiabetic neuropathyEnd pointsModelNeuropathyResearchTrial

More Related Videos

E-Patient Counseling Trial E-PACO: Computer Based Education versus Nurse Counseling for Patients to Prepare for Colonoscopy
06:28

E-Patient Counseling Trial E-PACO: Computer Based Education versus Nurse Counseling for Patients to Prepare for Colonoscopy

Published on: August 1, 2019

9.3K
In Silico Clinical Trials for Cardiovascular Disease
09:09

In Silico Clinical Trials for Cardiovascular Disease

Published on: May 27, 2022

2.4K

Related Experiment Videos

Last Updated: Mar 21, 2026

A Clinical Trial Assessing the Safety, Efficacy, and Delivery of Olive-Oil-Based Three-Chamber Bags for Parenteral Nutrition
04:53

A Clinical Trial Assessing the Safety, Efficacy, and Delivery of Olive-Oil-Based Three-Chamber Bags for Parenteral Nutrition

Published on: September 20, 2019

11.4K
E-Patient Counseling Trial E-PACO: Computer Based Education versus Nurse Counseling for Patients to Prepare for Colonoscopy
06:28

E-Patient Counseling Trial E-PACO: Computer Based Education versus Nurse Counseling for Patients to Prepare for Colonoscopy

Published on: August 1, 2019

9.3K
In Silico Clinical Trials for Cardiovascular Disease
09:09

In Silico Clinical Trials for Cardiovascular Disease

Published on: May 27, 2022

2.4K

Area of Science:

  • Neurology
  • Clinical Trial Design
  • Diabetic Complications

Background:

  • Diabetic sensorimotor polyneuropathy (DSP) is a common complication of diabetes.
  • Previous phase III trials have not demonstrated disease-modifying benefits for DSP.
  • Potential flaws in clinical trial design may explain these negative results.

Purpose of the Study:

  • To propose an optimized clinical trial design for evaluating disease-modifying therapies in DSP.
  • To identify key elements for successful future DSP clinical trials.

Main Methods:

  • The abstract proposes criteria for an ideal DSP clinical trial.
  • Key considerations include patient selection, intervention dosage, and trial duration.
  • Emphasis is placed on using objective endpoints like nerve conduction studies (NCS).

Main Results:

  • The abstract does not present results from a specific trial but outlines requirements for future trials.
  • Early or minimal disease stage, identified by NCS, is crucial for enrollment.
  • Sufficiently long trial durations (6-12 months for surrogate endpoints, 5-8 years for clinical benefits) are necessary.

Conclusions:

  • Current clinical trial designs may be inadequate for detecting disease-modifying effects in DSP.
  • Future trials require careful consideration of patient selection, intervention parameters, and extended follow-up periods.
  • Optimized trial design is essential to uncover effective treatments for DSP.